Advertisement
Research ArticleABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Renal Disposition of a Furan Dicarboxylic Acid and Other Uremic Toxins in the Rat

Yasuhiro Tsutsumi, Tsuneo Deguchi, Mikihisa Takano, Akira Takadate, W. Edward Lindup and Masaki Otagiri
Journal of Pharmacology and Experimental Therapeutics November 2002, 303 (2) 880-887; DOI: https://doi.org/10.1124/jpet.303.2.880

Abstract

The aim of this study was to understand the mechanisms that underlie the renal elimination of albumin-bound uremic toxins, particularly the highly bound furan acid 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF), that accumulate in chronic renal failure. These toxins inhibit the binding of acidic drugs and have various other untoward effects. The pharmacokinetics and tissue distribution of CMPF plus three other such toxins, indoxyl sulfate, indole acetic acid, and hippuric acid, have been examined in the anesthetized rat. The effects of p-aminohippuric (PAH) acid and tetraethylammonium on the uptake of CMPF by rat renal cortical slices in vitro were also investigated to characterize its mechanism of uptake. Plasma and tissue concentrations of the uremic toxins were determined by high-performance liquid chromatography. The rate of elimination of the toxins from plasma was indoxyl sulfate > hippuric acid > indole acetic acid > CMPF. Although the renal clearance of CMPF was low, its main elimination pathway was via urinary excretion with active tubular secretion. In renal cortical slice experiments, mutual inhibition between CMPF and PAH was observed. In addition, α-ketoglutarate stimulated the uptake of CMPF by renal cortical slices. The base tetraethylammonium did not inhibit slice uptake of CMPF. The pharmacokinetics of CMPF was characterized by slow plasma clearance and localization in the kidney. Furthermore, the evidence from experiments with renal cortical slices indicates that the uptake of CMPF is mediated by an anion/dicarboxylate exchanger, similar to that for PAH.

When kidney function is impaired, a variety of pathological changes occur that are collectively referred to as the uremic syndrome. A part of this syndrome involves elevated serum levels of a number of substances (Ringoir et al., 1987). In patients who have chronic renal failure, uremic toxins accumulate in the serum by a combination of the following four mechanisms: 1) a decrease in renal clearance (indoxyl sulfate), 2) an accumulation of abnormal metabolites (methylguanidine), 3) an increase in production (parathyroid hormone), and 4) a decreased rate of catabolism by the kidney (β2-microgloblin) (Niwa, 1996).

3-Carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF), a furan dicarboxylic acid derivative, was first detected in normal human urine in 1979 (Spiteller and Spiteller, 1979) and was subsequently isolated and identified in human blood (Pfordt et al., 1981). Since these initial reports, it has also been reported to accumulate in uremic plasma, reaching concentrations in the range of 60 to 370 μM (Niwa et al., 1988). In addition, a growing body of evidence suggests that it is a significant uremic toxin (Niwa, 1996).

CMPF has a high affinity for albumin (number of binding sites,n = 1; apparent association constant,Ka = 1.3 × 107 M−1) and inhibits the binding of other ligands, especially those that bind to site I (Lindup et al., 1986; Mabuchi and Nakahashi, 1988b; Henderson and Lindup, 1990;Sakai et al., 1995). It is believed to be a major factor in the decreased level of drug binding in uremic plasma because of its considerable affinity for albumin and also because of increased CMPF concentrations in uremic plasma. The concentration of CMPF can approach a 1:1 molar ratio with albumin, particularly when the production of albumin is reduced during chronic renal failure.

It has also been suggested that CMPF may play a role in a variety of pathological conditions, including the anemia that occurs during chronic renal failure (Niwa et al., 1990; Costigan et al., 1995), irregularities in thyroid function (Lim et al., 1993), and neurological symptoms that may be caused by the inhibition of organic anion transport at the blood-brain barrier (Costigan et al., 1996a). This furan dicarboxylic acid also inhibits phase I (O-demethylation) and phase II (glutathione conjugation and glucuronidation) pathways of drug metabolism in rabbit liver homogenates in vitro (Walters et al., 1995). In addition, there is evidence that CMPF inhibits active tubular secretion in the kidney (Henderson and Lindup, 1992). Thus, CMPF can be classified as a uremic toxin and, as a result, a compound of pharmacological interest.

Nevertheless, the mechanism by which CMPF accumulates remains unclear. To understand the pathway for the accumulation of CMPF, we have examined the pharmacokinetic properties of CMPF after intravenous administration and compared them with those of other uremic toxins, namely, indoxyl sulfate (IS), indole acetic acid (IA), and hippuric acid (HA). The renal and biliary excretion of CMPF and its tissue distribution after intravenous administration to the anesthetized rat have also been studied. We have also investigated the uptake of CMPF by renal cortical slices in vitro to see whether an organic anion/dicarboxylate exchanger was involved in the renal excretion of CMPF.

Materials and Methods

Materials.

CMPF was synthesized according to the method ofCostigan et al. (1996b), which was based on that of Pfordt et al. (1981). IS, IA, HA, p-aminohippuric acid (PAH), glutarate, and succinate were obtained from Nacalai Tesque (Kyoto, Japan). α-Ketoglutarate (α-KG) was obtained from Sigma-Aldrich (St. Louis, MO). Tetraethylammonium (TEA) was obtained from Wako Pure Chemicals (Osaka, Japan). Malonate was purchased from Tokyo Kasei (Tokyo, Japan), and methylsuccinate was bought from Aldrich Chemical Co. (Milwaukee, WI). All other chemicals were of analytical grade.

Pharmacokinetics of Uremic Toxins in the Anesthetized Rat.

Male Wistar rats (250–290 g; bred and maintained in the departmental animal facility) were anesthetized with sodium pentobarbital (60 mg/kg) by intraperitoneal injection, and the left femoral vein and artery were then cannulated.

All uremic toxins (CMPF, IS, IA, and HA) were administered at a dose of 5 mg/kg (21 μmol/kg) by rapid infusion into the femoral vein. After each infusion the cannulae were flushed with a small volume of heparinized saline to ensure that the complete dose was administered and to prevent the formation of clots.

Blood samples (200 μl) were taken from the femoral artery at 1, 3, 6, 15, 30, 60, 90, 120, 180, 240, and 300 min. The blood was placed in graduated microcentrifuge tubes (0.6 ml) that contained a drop of heparinized saline as anticoagulant. The blood samples were centrifuged (1500g for 10 min) and the plasma removed. With respect to CMPF, an aliquot (100 μl) of plasma was added to 1 ml of 1 M KH2PO4, and an aliquot of a stock solution of fenbufen was added as an internal standard. After this, 5 ml of ethyl acetate was added, and the samples were gently shaken for 15 min. After centrifugation at 1500g for 10 min, the organic phase (upper layer) was evaporated to dryness. The samples were then resuspended in 0.2 ml of 0.2 M acetate buffer, pH 4.5/acetonitrile/acetic acid (63:37:0.5, v/v/v), the mobile phase for the HPLC system. For the other uremic toxins (IS, IA, and HA), an aliquot of plasma sample (100 μl) was added directly to 200 μl of acetonitrile/water (1:2, v/v).

Determination of the Free (Unbound) Concentration of Uremic Toxins.

The serum-free concentrations of uremic toxins were estimated by ultrafiltration as described previously (Tsutsumi et al., 1999). The free fractions of uremic toxins were determined according to the following equation:f=(Cf/Ct)×100 (%) Equation 1where f represents free fraction of uremic toxin,Cf represents the free concentration, and Ct represents the total concentration of uremic toxin, respectively.

Urinary and Biliary Excretion.

The urinary excretion and biliary excretion of CMPF were measured to find the major excretory pathway of CMPF. Male Wistar rats (250–290 g; bred and maintained in the departmental animal facility) underwent a surgical procedure under light anesthesia with phenobarbital where cannulae were inserted into the femoral vein and artery, using polyethylene tubing (polyethylene-50; 0.58 mm i.d.; 0.9655 mm o.d.; BD Biosciences, Parsippany, NJ). The bile duct was also cannulated with polyethylene tubing (polyethylene-10; 0.28-mm i.d.; 0.61-mm o.d.), as was the bladder (polyethylene-8; 2.33-mm o.d.; Hibiki Co., Tokyo, Japan). The body temperature of the rats was maintained by heat from a lamp. Thirty minutes before the i.v. injection of CMPF, control samples of bile and urine were collected. Bile and urine were collected at 0 to 60, 60 to120, 120 to 180, 180 to 240, and 240 to 300 min.

Tissue Distribution of CMPF.

Rats were weighed and cannulated as described above. CMPF was then administered via the femoral vein, and 1 h later the rats were sacrificed by decapitation. The brain, heart, lungs, liver, spleen, kidneys, and testes were removed and weighed. A sample (0.5 g) of each tissue was homogenized in 3 ml of 1 M KH2PO4, and the CMPF therein was extracted using the procedure described for the preparation of plasma samples. The distribution of CMPF in each tissue is expressed as the concentration of CMPF per gram of each tissue divided by the concentration of CMPF in plasma (i.e., theCt/Cp ratio).

Uptake by Rat Renal Cortical Slices.

The uptake of CMPF and PAH by rat renal cortical slices was investigated using the procedure described by Henderson and Lindup (1992). Rats were anesthetized and the kidneys promptly removed, decapsulated, and placed in an ice-cold oxygenated rinse medium, which consisted of 97 mM NaCl, 40 mM KCl, 0.74 mM CaCl2 · 2H2O, and 7.5 mM sodium phosphate-chloride buffer, pH 7.4. Renal cortical slices (weight 10–20 mg/slice; about 0.5 mm in thickness) were cut freehand with Gillette valet strip blades to about 3 inches in length (Sabre International Products Ltd., Reading, UK). Two cortical slices were prepared from each half-kidney and were stored in the oxygenated rinse medium on ice for no longer than 15 min before the start of incubation. Two slices were placed in each flask and the medium (which consisted of rinse medium, 10 mM l-lactate, and 10 mMl-pyruvate) in each flask was thoroughly gassed with 100% oxygen for about 1 min both before and after the addition of the slices. A concentration of 20 μM was chosen for the substrate (CMPF) because this is the concentration normally found in healthy humans (Niwa et al., 1988). The flasks were then tightly sealed with rubber stoppers and incubated in a shaking water bath at 60 cycles/min for 60 min at 25°C. After the incubation, the flasks were placed on ice, the slices promptly removed from the flasks, gently blotted, and weighed. Tissue blanks were prepared by omission of CMPF from the incubation medium.

Another incubation medium (modified Cross and Taggart saline) was used to investigate the effect of α-KG on the uptake of CMPF and PAH by renal cortical slices and this contained 95 mM NaCl, 80 mM mannitol, 5 mM KCl, 0.74 mM CaCl2, and 9.5 mM Na2PO4, pH 7.4 (Pritchard, 1995).

For the renal cortical slice experiments, uptake of CMPF was expressed as the concentration of CMPF per gram of kidney tissue divided by the concentration of CMPF per milliliter of medium (i.e., the slice-to-medium ratio). Active uptake velocity was obtained by subtracting the uptake velocity in the presence of nitrogen (nonspecific uptake) from that in the presence of oxygen.

HPLC Conditions.

The HPLC system consisted of an L-6200 intelligent pump (Hitachi, Tokyo, Japan) and either an F-1050 fluorescence spectrophotometer or L-4000 UV detector (Hitachi). A column of LiChrosorb RP-18 (Cica Merck, Tokyo, Japan) was used as a stationary phase. The mobile phase consisted of acetate buffer (0.2 M, pH 4.5)/acetonitrile (93:7, v/v, for HA; 65:35, v/v, for IA and IS), acetate buffer (0.2 M, pH 4.5)/acetonitrile]/acetic acid (60:40:0.5, v/v, for CMPF), and methanol/acetonitrile/tetrahydrofuran/acetate buffer (70 mM, pH 4.0), which contained 3 mM tetra-n-butylammonium bromide (6.5:2:0.2:91.3, v/v, for PAH). The flow rate was 1.0 ml/min. HA, CMPF, and PAH were detected by UV at 240, 261, and 254 nm, respectively. IA and IS were detected by means of a fluorescence monitor. The excitation/emission wavelengths were 280/375 nm, respectively, for both IA and IS. The coefficients of variation of the HPLC methods were similar (<5%).

Data and Statistical Analysis.

Plasma concentration profiles were analyzed by fitting the following biexponential equation with the nonlinear least-squares method (MULTI) (Yamaoka et al., 1981).Cp=A·exp(α·t)+B·exp(−β·t) Equation 2Pharmacokinetics parameters were calculated using the following equations.AUC0→∞=A/α+B/β Equation 3CLtot=Dose/AUC Equation 4t1/2β=0.693/β Equation 5where area under the curve (AUC)0→∞,CLtot, andt1/2β represent AUC from zero to infinity, total body clearance, and half-life of the β phase, respectively.

All data are presented as the mean ± S.E., and nrefers to the number of animals used in each experiment. Student'st test was used to analyze differences between two groups. Analysis of variance was used to analyze differences among more than two groups, and the significance of difference between two means in these groups was evaluated using the modified Fisher's least-squares difference method.

Results

The recovery of authentic CMPF, IS, IA, and HA from rat plasma was greater than 95% in each case. Normal rat plasma contained substances that have chromatographic characteristics that are identical to CMPF, IS, IA, and HA, and the mean (±S.E.) endogenous concentrations of these substances were 0.85 ± 0.06, 1.62 ± 0.17, 0.25 ± 0.04, and 1.25 ± 0.14 μg/ml, respectively (n= 5).

Pharmacokinetics of Uremic Toxins.

Fig.1 shows the plasma-time concentration profiles for the uremic toxins after administration of doses of 5 mg/kg to the rats. The plasma clearance of CMPF was the lowest of all the uremic toxins tested in this experiment (Table1). The biological half-life (t1/2β) was 356 ± 18 min (Table 1), and this value seems to reflect its high affinity for albumin (the percentage bound was about 98%; Table 1). IS, however, which had a similar unbound fraction (2%) to CMPF in rat plasma under the conditions of this experiment, was eliminated from plasma much more rapidly than CMPF. Other uremic toxins, including IA and HA, had a moderate plasma clearance and a lower affinity for albumin than either CMPF or IS.

Figure 1
Figure 1

Plasma concentration-time profiles for a series of uremic toxins. All uremic toxins (●, CMPF; ▪, IA; ■, HA; and ○, IS) were administered at a dose of 5 mg/kg by rapid infusion into the femoral vein. Blood samples were taken from the femoral artery at 1, 3, 6, 15, 30, 60, 90, 120, 180, 240, and 300 min. Each point represents the mean ± S.E. of four different experiments.

View this table:
Table 1

Pharmacokinetic parameters for uremic toxins after i.v. administration (5 mg/kg)

The urinary and biliary excretion of CMPF were also examined. The renal (CLr,f) and biliary (CLb,f) clearances of unbound CMPF were 14.3 ± 0.6 and 0.09 ± 0.01 ml/min kg, respectively. Most of the CMPF was excreted unchanged and the main route was via the urine (Table2). It is noteworthy in this respect that the main elimination pathway of the other uremic toxins was also via renal excretion (Table 3). When the renal clearance of unbound CMPF (CLr,f) is compared with the glomerular filtration rate (GFR), the results suggest that active tubular secretion is involved in the urinary excretion of CMPF (Table 2). These results are consistent with the finding that CMPF is mainly distributed in the kidney. The concentration of CMPF in the kidney after 1 h (at the 5-mg/kg dose) was 34.3 μg/g, after intravenous administration (Fig. 2). The low renal clearance of CMPF may be due to the saturation of tubular secretion at a 5-mg/kg dose in the rat. Because of this, the dose dependence of CMPF was examined. Plasma clearance decreased with increasing the dose from 1 to 5 mg/kg (Table4), suggesting that at 5 mg/kg, tubular secretion, which is responsible for the plasma clearance of CMPF, was saturated.

View this table:
Table 2

Total and renal clearance and hemodynamic parameter for CMPF

View this table:
Table 3

Total and renal clearance of uremic toxins after i.v. administration (5 mg/kg)

Figure 2
Figure 2

Tissue distribution of CMPF after i.v. administration. CMPF was administered at a dose of 5 mg/kg via the femoral vein and 1 h later various tissues were removed. The distribution of CMPF in each tissue is expressed as theCt/Cp ratio, i.e., the concentration of CMPF per gram of each tissue divided by the concentration of CMPF in plasma (28.5 μg/ml) at 1 h after administration.

View this table:
Table 4

Dose-dependent pharmacokinetics for CMPF after i.v. administration

Mechanism of Uptake of CMPF by Renal Cortical Slices.

The uptake of CMPF by renal cortical slices was examined next. In the presence of oxygen, the slice-to-medium ratio was 4.6 ± 0.5 (n = 3), whereas under anaerobic conditions (in the presence of nitrogen), this value was 1.1 ± 0.2 (n = 3). These results suggest that active transport is involved in the uptake of CMPF by renal cortical slices and provides further support for the above-mentioned in vivo data. The active uptake of CMPF by renal cortical slices was linear for at least 20 min (data not shown). To estimate the Km andVmax values for the active uptake of CMPF from the initial rate, the uptake velocity of CMPF over a range of concentrations (20–320 μM) was measured after incubation for 20 min at 25°C in three separate experiments. Nonspecific uptake measured in the absence of oxygen was subtracted from the uptake in the presence of oxygen. The mean Km andVmax values for the active uptake of CMPF were 98.1 ± 15.2 μM and 36.7 ± 10.2 nmol/min/g kidney, respectively. These values were smaller than those reported byHenderson and Lindup (1992) (Km = 194 μM; Vmax = 55 nmol/min/g kidney) who used a longer incubation time of 90 min. In the present study,Km andVmax values were calculated from the initial rate and therefore the affinity of the renal uptake system for CMPF may be higher than reported previously.

As shown in Fig. 3, the uptake of CMPF by renal cortical slices was inhibited by PAH, a typical substrate for an organic anion transporter in the kidney. CMPF uptake by renal cortical slices was concentration dependent over the range 20 μM to 1 mM. PAH (1 mM) produced a significant reduction in CMPF uptake (7.76 ± 2.93% of the uptake in the control study). The apparent inhibitory constant (Ki) of PAH to inhibit the CMPF uptake, determined from a Dixon plot, was 97.4 μM. CMPF uptake was not inhibited by TEA, a typical substrate for an organic cation transporter in the kidney. These results suggest that organic anion transporters, which recognize PAH as a substrate, are also involved in the active uptake of CMPF by renal cortical slices.

Figure 3
Figure 3

Dose-dependent inhibitory effect of PAH and TEA on the uptake of CMPF by renal cortical slices. The values are expressed as a percentage of 20 μM CMPF uptake by renal cortical slices at 25°C for 1 h in the absence of inhibitor. The ordinate represents the percentage of control renal uptake for CMPF, and the abscissa represents the logarithm of the concentration of PAH (●) and TEA (○) in the incubation buffer. Each point represents the mean ± S.E. of four to five separate experiments. Each slice was prepared from a different rat. P < 0.05 (a),P < 0.01(b), significantly different from corresponding control CMPF uptake.

To estimate the inhibitory effect of CMPF on the organic anion transport system, we investigated the effect of CMPF on the uptake of PAH by renal cortical slices. As shown in Fig.4, CMPF inhibited the uptake of PAH in a concentration-dependent manner. At 400 μM, CMPF inhibited the uptake of PAH by 81%. The Ki value of CMPF for inhibition of PAH uptake was 91 μM. The mutual inhibition suggests that PAH and CMPF shared the transport system.

Figure 4
Figure 4

Effect of CMPF on the uptake of PAH by renal cortical slices. The values are expressed as a percentage of 20 μM PAH uptake by renal cortical slices at 25°C for 1 h in the absence of CMPF. Each column represents the mean ± S.E. of three different experiments. P < 0.05 (a), P< 0.01 (b), significantly different from control.

Characterization of the CMPF Transport System in Renal Cortical Slices.

It is well known that the active transport of PAH across the basolateral membrane occurs as the result of the coupling of two transport processes: Na+-dicarboxylate symport and PAH-dicarboxylate exchange (Pritchard, 1995; Orlov Yu, 1997). Because of the mutual inhibition between PAH and CMPF in the renal cortical slice experiments, the same mechanism seems to be involved in the uptake of CMPF. To confirm whether the uptake of CMPF might be mediated by the same transport system, we investigated the effect of α-KG on the uptake of CMPF by rat renal cortical slices.

As has been shown previously for PAH (Pritchard, 1990, 1995), the external addition of α-KG resulted in a biphasic and lithium-sensitive effect on the uptake of 20 μM CMPF by rat renal cortical slices (Fig. 5). Peak stimulation was observed at an α-KG concentration of 50 μM, and uptake was decreased at higher concentrations. Furthermore, 5 mM lithium completely blocked the stimulatory effect of 50 μM α-KG. Based on these observations, we propose that an organic anion/dicarboxylate exchanger is involved in the uptake of CMPF by rat kidney slices, in the same manner as for PAH.

Figure 5
Figure 5

Stimulation of CMPF uptake in renal cortical slices by external α-KG. CMPF uptake was assessed after a 30-min incubation with 20 μM CMPF and 0 to 400 μM α-KG at 25°C in the modified Cross and Taggart saline. Lithium (5 mM) completely blocked the stimulation produced by 50 μM α-KG. Each column represents the mean ± S.E. of four to five different experiments. a,P < 0.01 versus control (no added α-KG). b,P < 0.01 versus 50 μM α-KG.

The Na+-dicarboxylate transport system has Na+ and Li+ dependence (Pritchard, 1990; Pajor, 1999). To obtain further evidence about whether the organic anion/dicarboxylate exchanger was responsible for the uptake of CMPF in the kidney, the ionic dependence of CMPF uptake was investigated by measuring CMPF uptake in the presence of various inorganic salts (Table 5). Control uptake was measured in the presence of NaCl. Replacement of Na+ with an equimolar concentration of cations such as K+ and choline inhibited the uptake of CMPF by 38.9 ± 2.3 and 43.5 ± 7.2%, respectively. This indicates that the renal uptake of CMPF was diminished by inhibition of Na+-dicarboxylate symport, which links with the organic anion/dicarboxylate exchanger. Replacement of Na+ with Li+ decreased the uptake by 31.2 ± 8.7%, but its inhibitory effect was weaker than that of K+ and choline. Moreover, in the presence of NaCl and 5 mM LiCl, the uptake of CMPF was reduced by 26.4 ± 8.6%. These results indicate that transport of CMPF was sensitive to Li+, and so the organic anion/dicarboxylate exchanger could be involved in the transport of CMPF in the kidney.

View this table:
Table 5

Influence of monovalent cations on the uptake of CMPF by renal cortical slices

We also examined the inhibitory effect of various dicarboxylates on CMPF uptake by renal cortical slices (Table6). α-KG and glutarate, substrates and/or inhibitors of the organic anion transport system and Na+-dicarboxylate symport (Sekine et al., 1997;Uwai et al., 1998; Kekuda et al., 1999), inhibited CMPF uptake by 88.5 ± 4.1 and 64.4 ± 6.3%, respectively. Succinate and methylsuccinate, which are substrates of Na+-dicarboxylate symport but not inhibitors of the organic anion/dicarboxylate exchanger, also reduced the uptake by 39.0 ± 7.3 and 47.7 ± 8.5%, respectively. Malonate, which is not an inhibitor of either the Na+-dicarboxylate symport or the organic anion/dicarboxylate exchanger, did not inhibit (Table 6). These observations suggest that the organic anion transport system plays an important role in the uptake process of CMPF in the kidney.

View this table:
Table 6

Effect of dicarboxylate on the uptake of CMPF by the renal cortical slice

Discussion

The half-life of CMPF was longer than that of the other uremic toxins investigated in this study, in which IS was eliminated the most rapidly. CMPF and IS were bound to nearly to the same extent in rat plasma in these experiments (Table 1), and the data in Table 3 show that the elimination of CMPF and IS from plasma is a function of urinary excretion. We conclude that this difference in rate of elimination is based on differences in affinity for the renal active transport system.

The elimination of IS was more rapid than that of IA, which, like IS, is an indole derivative. IS contains a sulfate group, unlike IA. Sulfate conjugates, such as estrone sulfate and dehydroepiandrosterone sulfate, are high-affinity substrates for the various organic anion transporters (Kusuhara et al., 1999; Cha et al., 2000; Van Aubel et al., 2000). This points to the importance of the sulfate group in the recognition of compounds and their excretion by the transport system. The total clearance of IS was the same as renal clearance, and the renal clearance of IS divided by the free fraction (f = 0.02), which was much higher than that of the other uremic toxins, was about 41 times greater than the GFR (7.32 ml/min/kg; Trumper et al., 1998). This suggests that either the transport mechanism for IS or the affinity of IS for the organic anion transporters may differ from that for carboxylate derivatives (IA, HA, and CMPF).

The elimination of CMPF, a dicarboxylic acid, was slower than that of IA and HA, which are monocarboxylic acid derivatives. Among these carboxylic acid derivatives, the rank order of total renal clearance was the same as that of the free fraction, and therefore renal clearance of the free fraction of these carboxylic acid derivatives was the same (Tables 1 and 3). This suggests that plasma protein binding affects the rate of glomerular filtration and also the concentration of the carboxylic acid derivative that can access the transporter at the basolateral membrane, i.e., the higher the protein binding, the lower is the glomerular filtration rate and total renal clearance. The present data indicated that CMPF is almost totally excreted via the kidney (Table 2), mostly unchanged. CMPF can inhibit phase I (O-demethylation) and phase II (glutathione conjugation and glucuronidation) pathways of drug metabolism in the liver (Mabuchi and Nakahashi, 1988a; Walters et al., 1995). It seems that CMPF may act as an inhibitor of drug metabolism but not be metabolized itself. The renal transport system may therefore play an important role in the elimination of CMPF.

Because CMPF has a high affinity for albumin and is effectively excreted in urine, it is likely that an active transport system, such as an organic anion transporter is involved in its elimination from the kidney. It is reasonable to assume that CMPF is mainly eliminated by this mechanism because CMPF is an organic acid that structurally possesses the required hydrophobic area and two negative partial charges (Ullrich and Rumrich, 1988; Ullrich, 1997). Costigan and Lindup (1996) reported that the plasma clearance of CMPF is decreased as a result of the coadministration of PAH and probenecid. In addition, mutual inhibition between PAH and CMPF was observed in slice uptake experiments (Figs. 3 and 4), suggesting that the same transport system is shared with both PAH and CMPF.

The first step in active secretion is the extraction of organic anions from the peritubular blood plasma by the proximal tubule cells through the basolateral membrane. This basolateral uptake of organic anions has been extensively investigated with PAH as the test substrate. According to the proposed model (Pritchard, 1995; Orlov Yu, 1997), the first stage is the formation of a Na+ gradient as the result of the hydrolysis of ATP by Na+,K+-ATPase. This Na+ gradient is a driving force for the Na+-dicarboxylate symport, which is sensitive to lithium (Pritchard, 1990; Pajor, 1999). As a result, an anion gradient (dicarboxylate) develops, which is directed from the cell. During the last step, the dicarboxylate anion is exchanged for PAH by the anion exchange transporter. Our observations also suggest that CMPF is recognized by an organic anion/dicarboxylate exchanger because the renal uptake of CMPF was markedly stimulated by 50 μM α-KG, and this stimulation was prevented by not only the presence of 400 μM α-KG but also the addition of 5 mM lithium (Fig. 5). Based on these observations, we propose that an organic anion/dicarboxylate exchanger is involved in the uptake of CMPF, in the same manner as for PAH.

To obtain further evidence about whether the organic anion/dicarboxylate exchanger was responsible for the uptake of CMPF in the kidney, the ionic dependence of CMPF uptake was investigated (Table5). Replacement of Na+ with an equimolar concentration of cations such as K+, choline, and lithium inhibited the uptake of CMPF by 38.9 ± 2.3, 43.5 ± 7.2, and 31.2 ± 8.7%, respectively. These results support the view that the organic anion/dicarboxylate exchanger could be involved in the transport of CMPF in the kidney, because the organic anion/dicarboxylate exchanger is coupled with Na+-dicarboxylate symport. Furthermore, CMPF uptake by renal cortical slices was strongly inhibited by α-KG and glutarate, which are substrates and/or inhibitors of the organic anion transport system and Na+-dicarboxylate symport (Sekine et al., 1997; Uwai et al., 1998; Kekuda et al., 1999) (Table6). These results suggest that the organic anion transport system could play an important part in the uptake process for CMPF in the kidney.

On the other hand, it is possible that CMPF is transported by Na+-dicarboxylate symport because CMPF is a dicarboxylic acid. Transport systems for dicarboxylates have been studied in the vesicles from brush-border membranes and basolateral membranes (Wright, 1985; Wright and Wunz, 1987), mostly with succinate as a test substrate. Succinate is a high-affinity substrate for the Na+-dependent dicarboxylate transporter (NaDC3;Kt of succinate = 2 μM), which is present in the rat kidney (Kekuda et al., 1999). However, succinate exhibited only a moderate inhibitory effect on the uptake of CMPF by renal slices (Table 6). Furthermore, no inhibitory effect of 1 mM CMPF on the uptake of [14C]succinate by renal slices was observed (data not shown). These data suggest that CMPF and succinate would be transported by different carriers, and the contribution of Na+-dicarboxylate symport to the uptake of CMPF in the kidney would be very low. Considering the relatively little inhibition produced either by the replacement of Na+ (Table 5) or by succinate (Table 6), the effects on the uptake of CMPF may be secondary to the inhibition of Na+-dicarboxylate symport. This points to the importance of the organic anion transport system for CMPF excretion in the kidney. However, further work is needed to identify the CMPF transporter, and experiments with expression systems are needed to assess the contribution of individual transporters.

Recently, Sekine et al. (1997) reported the functional expression cloning of an organic anion/dicarboxylate exchanger (OAT1) and its characteristics as a multispecific organic anion transporter. They demonstrated that OAT1 plays an essential role in the elimination of numerous organic anions and that an outwardly directed dicarboxylate gradient is essential for expressing transport activity (Sekine et al., 2000). The necessity of the dicarboxylate gradient for the transport of CMPF suggests that OAT1 plays an important role in the elimination of CMPF. Moreover, other isoforms, named OAT2 and OAT3, are also expressed in the kidney and are sensitive to PAH (Sekine et al., 1998; Kusuhara et al., 1999; Kojima et al., 2002). In particular, CMPF may be a substrate of OAT3, because CMPF is a potent inhibitor of OAT3 expressed in oocytes (IC50 of CMPF = 4 μM) (Deguchi et al., 2002). These transporters may be responsible for the renal uptake of CMPF, because there was mutual inhibition of slice uptake between CMPF and PAH in the uptake experiments (Figs. 3 and 4;Henderson and Lindup, 1992).

In uremia, the accumulation of CMPF has various effects, i.e., inhibition of protein binding (Sakai et al., 1995), inhibition of drug metabolism (Walters et al., 1995), and inhibition of renal excretion (Henderson and Lindup, 1992; Walters et al., 1995). CMPF may therefore cause other uremic metabolites and/or drugs to remain in circulation and elevate their concentrations to toxic levels. Interestingly, however, the free fraction of CMPF was low, but its concentration in the kidney was almost the same as that of plasma (Fig. 2). Based upon this observation, CMPF may affect pharmacokinetics of drugs by inhibition of metabolism and renal excretion. This leads us to the suggestion that organic anion transport systems play an important role not only the elimination of CMPF via the kidney but also in mediating the uremic toxicity of CMPF. Furthermore, it has been reported that an organic anion/dicarboxylate exchanger also exists in the brain (Adkison and Shen, 1996; Sekine et al., 2000) as well as the kidney. These transporters also recognize drugs and endogenous compounds, and so a study of the effects of CMPF on such transporters will lead to a better understanding of not only drug-uremic toxin interactions but also the relationship between the uremic syndrome and uremic toxins.

In conclusion, we have found that CMPF is cleared more slowly from rat plasma than indoxyl sulfate, hippuric acid, or indole acetic acid and that the highest tissue concentration was found in the kidney. Furthermore, using renal cortical slices, we conclude that the uptake of CMPF would be mediated by an anion/dicarboxylate exchanger that is similar to that for PAH.

Footnotes

  • Abbreviations:
    CMPF
    3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid
    IS
    indoxyl sulfate
    IA
    indole acetic acid
    HA
    hippuric acid
    PAH
    p-aminohippuric acid
    α-KG
    α-ketoglutarate
    TEA
    tetraethylammonium
    HPLC
    high-performance liquid chromatography
    CL
    clearance
    GFR
    glomerular filtration rate
    OAT
    organic anion transporter
    • Received November 30, 2001.
    • Accepted July 17, 2002.

References

  1. ↵
    1. Adkison KD,
    2. Shen DD
    (1996) Uptake of valproic acid into rat brain is mediated by a medium-chain fatty acid transporter. J Pharmacol Exp Ther 276:1189–1200.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Cha SH,
    2. Sekine T,
    3. Kusuhara H,
    4. Yu E,
    5. Kim JY,
    6. Kim DK,
    7. Sugiyama Y,
    8. Kanai Y,
    9. Endou H
    (2000) Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem 275:4507–4512.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Costigan MG,
    2. Callaghan CA,
    3. Lindup WE
    (1996a) Hypothesis: is accumulation of a furan dicarboxylic acid (3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid) related to the neurological abnormalities in patients with renal failure? Nephron 73:169–173.
    OpenUrlPubMed
  4. ↵
    1. Costigan MG,
    2. Gilchrist TL,
    3. Lindup WE
    (1996b) Synthesis and physicochemical properties of the furan dicarboxylic acid, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, an inhibitor of plasma protein binding in uraemia. J Pharm Pharmacol 48:635–640.
    OpenUrlPubMed
  5. ↵
    1. Costigan MG,
    2. Lindup WE
    (1996) Plasma clearance in the rat of a furan dicarboxylic acid which accumulates in uremia. Kidney Int 49:634–638.
    OpenUrlPubMed
  6. ↵
    1. Costigan MG,
    2. Yaqoob M,
    3. Lindup WE
    (1995) Effects of haemodialysis and continuous ambulatory peritoneal dialysis on the plasma clearance of an albumin-bound furan dicarboxylic acid. Nephrol Dial Transplant 10:648–652.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Deguchi T,
    2. Ohtsuki S,
    3. Otagiri M,
    4. Takanaga H,
    5. Asaba H,
    6. Mori S,
    7. Terasaki T
    (2002) Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney. Kidney Int 61:1760–1768.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Henderson SJ,
    2. Lindup WE
    (1990) Interaction of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, an inhibitor of plasma protein binding in uraemia, with human albumin. Biochem Pharmacol 40:2543–2548.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Henderson SJ,
    2. Lindup WE
    (1992) Renal organic acid transport: uptake by rat kidney slices of a furan dicarboxylic acid which inhibits plasma protein binding of acidic ligands in uremia. J Pharmacol Exp Ther 263:54–60.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Kekuda R,
    2. Wang H,
    3. Huang W,
    4. Pajor AM,
    5. Leibach FH,
    6. Devoe LD,
    7. Prasad PD,
    8. Ganapathy V
    (1999) Primary structure and functional characteristics of a mammalian sodium-coupled high affinity dicarboxylate transporter. J Biol Chem 274:3422–3429.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Kojima R,
    2. Sekine T,
    3. Kawachi M,
    4. Cha SH,
    5. Suzuki Y,
    6. Endou H
    (2002) Immunolocalization of multispecific organic anion transporters, OAT1, OAT2 and OAT3, in rat kidney. J Am Soc Nephrol 13:848–857.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Kusuhara H,
    2. Sekine T,
    3. Utsunomiya-Tate N,
    4. Tsuda M,
    5. Kojima R,
    6. Cha SH,
    7. Sugiyama Y,
    8. Kanai Y,
    9. Endou H
    (1999) Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem 274:13675–13680.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Lim CF,
    2. Bernard BF,
    3. de Jong M,
    4. Docter R,
    5. Krenning EP,
    6. Hennemann G
    (1993) A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. J Clin Endocrinol Metab 76:318–324.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Tillement J-P,
    2. Lindenlaub E
    1. Lindup WE,
    2. Bishop KA,
    3. Collier R
    (1986) Drug binding defect of uraemic plasma: contribution of endogenous binding inhibitors. in Protein Binding Drug Transport. (Symposia Medica Hoechst 20) eds Tillement J-P, Lindenlaub E (FK Schattauer Verlag Stuttgart, New York), pp 397–414.
  15. ↵
    1. Mabuchi H,
    2. Nakahashi H
    (1988a) Inhibition of hepatic glutathione S-transferases by a major endogenous ligand substance present in uremic serum. Nephron 49:281–283.
    OpenUrlPubMed
  16. ↵
    1. Mabuchi H,
    2. Nakahashi H
    (1988b) A major inhibitor of phenytoin binding to serum protein in uremia. Nephron 48:310–314.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Niwa T
    (1996) Organic acids and the uremic syndrome: protein metabolite hypothesis in the progression of chronic renal failure. Semin Nephrol 16:167–182.
    OpenUrlPubMed
  18. ↵
    1. Niwa T,
    2. Takeda N,
    3. Maeda K,
    4. Shibata M,
    5. Tatematsu A
    (1988) Accumulation of furancarboxylic acids in uremic serum as inhibitors of drug binding. Clin Chim Acta 173:127–138.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Niwa T,
    2. Yazawa T,
    3. Kodama T,
    4. Uehara Y,
    5. Maeda K,
    6. Yamada K
    (1990) Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis. Nephron 56:241–245.
    OpenUrlPubMed
  20. ↵
    1. Orlov Yu N
    (1997) Mechanisms of secretion of toxic organic anions in mammalian kidneys. Membr Cell Biol 11:417–429.
    OpenUrlPubMed
  21. ↵
    1. Pajor AM
    (1999) Sodium-coupled transporters for Krebs cycle intermediates. Annu Rev Physiol 61:663–682.
    OpenUrlCrossRefPubMed
  22. ↵
    Pfordt J, Thoma H, and Spiteller G (1981) Identifizierung, strukuturableitung und synthese bisher unbekannte urofuransauren im menschlichen bult. Liebigs Ann Chem:2298–2308..
  23. ↵
    1. Pritchard JB
    (1990) Rat renal cortical slices demonstrate p-aminohippurate/glutarate exchange and sodium/glutarate coupled p-aminohippurate transport. J Pharmacol Exp Ther 255:969–975.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Pritchard JB
    (1995) Intracellular alpha-ketoglutarate controls the efficacy of renal organic anion transport. J Pharmacol Exp Ther 274:1278–1284.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Ringoir S,
    2. Vanholder R,
    3. Massry S
    (1987) Uremic Toxins. (Plenum Press, New York).
  26. ↵
    1. Sakai T,
    2. Takadate A,
    3. Otagiri M
    (1995) Characterization of binding site of uremic toxins on human serum albumin. Biol Pharm Bull 18:1755–1761.
    OpenUrlPubMed
  27. ↵
    1. Sekine T,
    2. Cha SH,
    3. Endou H
    (2000) The multispecific organic anion transporter (OAT) family. Pfluegers Arch 440:337–350.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Sekine T,
    2. Cha SH,
    3. Tsuda M,
    4. Apiwattanakul N,
    5. Nakajima N,
    6. Kanai Y,
    7. Endou H
    (1998) Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett 429:179–182.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Sekine T,
    2. Watanabe N,
    3. Hosoyamada M,
    4. Kanai Y,
    5. Endou H
    (1997) Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem 272:18526–18529.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Spiteller M,
    2. Spiteller G
    (1979) [Separation and characterization of acidic urine constituents (author's translation). J Chromatogr 164:253–317.
    OpenUrlPubMed
  31. ↵
    1. Trumper L,
    2. Monasterolo LA,
    3. Elias MM
    (1998) Probenecid protects against in vivo acetaminophen-induced nephrotoxicity in male Wistar rats. J Pharmacol Exp Ther 284:606–610.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Tsutsumi Y,
    2. Maruyama T,
    3. Takadate A,
    4. Goto M,
    5. Matsunaga H,
    6. Otagiri M
    (1999) Interaction between two dicarboxylate endogenous substances, bilirubin and an uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, on human serum albumin. Pharm Res 16:916–923.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Ullrich KJ
    (1997) Renal transporters for organic anions and organic cations. Structural requirements for substrates. J Membr Biol 158:95–107.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Ullrich KJ,
    2. Rumrich G
    (1988) Contraluminal transport systems in the proximal renal tubule involved in secretion of organic anions. Am J Physiol 254:F453–F462.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Uwai Y,
    2. Okuda M,
    3. Takami K,
    4. Hashimoto Y,
    5. Inui K
    (1998) Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Lett 438:321–324.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Van Aubel RA,
    2. Masereeuw R,
    3. Russel FG
    (2000) Molecular pharmacology of renal organic anion transporters. Am J Physiol Renal Physiol 279:F216–F232.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Walters R,
    2. Nicholls P,
    3. Lindup WE
    (1995) Effect of three uremic toxins on various pathways of hepatic drug metabolism in vitro. J Pharm Pharmacol 47:1091.
    OpenUrl
  38. ↵
    1. Wright EM
    (1985) Transport of carboxylic acids by renal membrane vesicles. Annu Rev Physiol 47:127–141.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Wright SH,
    2. Wunz TM
    (1987) Succinate and citrate transport in renal basolateral and brush-border membranes. Am J Physiol 253:F432–F439.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    1. Yamaoka K,
    2. Tanigawara Y,
    3. Nakagawa T,
    4. Uno T
    (1981) A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4:879–885.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Renal Disposition of a Furan Dicarboxylic Acid and Other Uremic Toxins in the Rat

Yasuhiro Tsutsumi, Tsuneo Deguchi, Mikihisa Takano, Akira Takadate, W. Edward Lindup and Masaki Otagiri
Journal of Pharmacology and Experimental Therapeutics November 1, 2002, 303 (2) 880-887; DOI: https://doi.org/10.1124/jpet.303.2.880
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement